23 July 2026
In plain English
Today is the day. The FDA's peptide advisory panel meets this morning (US time) to decide whether a set of experimental recovery-and-longevity drugs — led by BPC-157, the most popular — can be legally custom-made at specialty pharmacies. Barque has carried two bets into this vote for three months, and both resolve tonight once the panel votes. The one thing that moved overnight actually helps our main call: after critics said the panel had been packed with people who sell and prescribe peptides, the FDA added eight more experts that a former agency official called "more qualified and less conflicted." A less-conflicted panel is likelier to side with the FDA's own scientists, who recommend against every drug on the list — so we nudged our "no green light" bet up a touch and our "at least two get approved" bet down. Worth knowing: these drugs already came off the restricted list in April, so a "no" today bans nothing new — it just declines to open a legal path. Everything else is quiet.
Signal detail
(BPC-157 does NOT get the FDA permitted list today) T-0. The material overnight development is panel composition, and it cuts our way. Per [Bloomberg Law](https://news.bloomberglaw.com/health-law-and-business/fda-adds-more-peptide-panel-experts-after-conflict-criticism), the FDA — responding to criticism that the reconstituted PCAC was stacked with peptide-business ties — added eight temporary voters (Durham, Iadecola, Lee, Mailman, Sandbrink, Skelsey, Zacharoff, Zamboni) spanning GI, neurology, pain, addiction, dermatology and cancer pharmacology. Former FDA official Peter Lurie called them "considerably more qualified and less conflicted." That directly dilutes the engineered-override tail the log fattened July 21–22 on the first wave of additions alone. Set against staff-against-all-7 + the advisory-follows-staff base rate (~75–80%) + a FAERS-documented BPC-157 hospitalization, NOT-Cat-1 strengthens. Skeptic/Bayesian did not diverge; small delta, not re-flagged — still flagged for operator resolution after tonight's vote.
(fewer than two of the four Day-1 peptides get Cat 1) Same evidence, opposite sign. A less-conflicted panel is more likely to follow staff, who state human clinical evidence is absent for KPV, TB-500 and MOTs-C (TB-500 additionally carries a PSM tumor-proliferation concern). The 2-of-4 basket needs two correlated overrides against that; the panel-dilution news makes the deferential scenario likelier. 0.38 → 0.32, internally consistent with BPC-157 (the weakest) near 0.27 to pass. Flagged for operator resolution after the vote.
— Month 19+ post-facility-acquisition. Hims's "Not all peptides are created equal" campaign is live, the stock hit a [2026 high](https://finance.yahoo.com/markets/stocks/articles/hims-stock-hits-2026-high-014158019.html) after unlocking $400M working capital via JPMorgan, and [Fortune](https://fortune.com/2026/07/20/the-fda-peptide-vote-could-create-telehealths-next-multibillion-dollar-market-telehealth-hims-ro-glp1-ozempic-injectables/) frames today's vote as telehealth's next multibillion-dollar market. No launch announcement. A same-day denial marginally raises 2026 delay risk, but the Dec-31 horizon and launch-first-retreat pattern hold 0.85.
— Convergence-week coverage is intensifying (Fortune Jul 20, Forbes Jul 21, NPR-affiliate [WWNO](https://www.wwno.org/npr-news/2026-07-22/peptides-get-their-regulatory-closeup) Jul 22), but still no top-5 national investigative feature on injuries, contamination or deaths. The FAERS BPC-157 hospitalization and April import alerts stay citation-ready. 252 days to resolution.
— Day 23 post-launch. CMS now cites ~3.4M eligible in year one (vs KFF's 3.8M), $245 net / $50 copay, Humana as central processor via LI NET. No enrollment data, no operational failures, near-zero bridge search demand in our GSC. First pharmacy-claims data expected late July; year-one Part D base rates keep sub-1M dominant.
— First-party Katalys posted 2 conversions / $450 this week (prior $1,649), clicks −8%, GSC impressions −32% — a soft-revenue week reading as conversion lumpiness (Trim Rx $300, Embody $150), not a thesis change. Zero peptide-DTC affiliates in the network; a likely no-vote further delays any compliant peptide affiliate surface. GLP-1 CPA dominance ($260–500 vs peptide $0) is structural.
Resolutions & upcoming
Nothing resolved today. Two forecasts resolve tonight once PCAC votes Day 1 (BPC-157, KPV, TB-500, MOTs-C): `bpc157-pcac-2026` and `pcac-july-multi-peptide`. Ra does not auto-resolve — the operator writes the outcome and final Brier after the vote count is public (expect trade coverage within hours, FDA transcript within days). No other forecast resolves inside 14 days.
How Barque got smarter today
- Date-drift caught. Briefs July 20–22 repeatedly called the vote "Wednesday." July 23 is a Thursday (FDA calendar: Thursday–Friday). Corrected. Adding a resolution-day weekday check to the pre-vote ritual.
- Panel composition is a two-wave story, not one. The log locked onto the June 29 "stacked with peptide sellers" framing and over-weighted the override tail July 21–22. The FDA then diluted the panel with more-qualified, less-conflicted experts after criticism. Failure mode: single-narrative lock-in on a vivid first-wave signal. Fix applied today, one day late.
- Augur pick — "a No re-bans nothing." All seven peptides came off the Category 2 list April 23, so today's vote is asymmetric: a Yes opens a new legal 503A pathway, a No merely preserves the current gray-market status quo. This reframes how a No should read for the Hims and safety-incident forecasts — a No is a non-event for existing supply, not a crackdown.
- Quiet-day discipline held. Only PCAC evidence justified a move; the five non-vote forecasts stayed put rather than manufacturing motion on convergence-week noise.